← Back to headlines
OPKO Health Shares Surge on Strong 2026 Revenue Guidance and Q2 Beats
OPKO Health's shares surged after the company outlined a 2026 revenue guidance of $560 million to $585 million and reported better-than-expected second-quarter results. The company also plans to begin clinical trials for MDX3001 by late 2026 or early 2027.
28 Jul, 01:29 — 28 Jul, 01:29
Sources
Showing 1 of 1 sources
Related Stories
Debate Over Aerial Pesticide Spraying in Philippine Sugarcane Fields
just now
Philippine President Marcos Pushes to Abolish Electricity System Loss Charges
just now
Filipinos Prioritize Cost of Goods as Top Issue for Marcos Administration
just now
DENR Opens Satellite Office in Southern Marinduque
just now